Comparative Pharmacology
Head-to-head clinical analysis: FETZIMA versus SAVELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETZIMA versus SAVELLA.
FETZIMA vs SAVELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fetzima (levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine, with approximately 2-fold higher potency for norepinephrine reuptake inhibition, which enhances neurotransmission in the central nervous system.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); also weakly inhibits dopamine reuptake. Binds to serotonin and norepinephrine transporters, increasing their extracellular concentrations.
20 mg orally once daily for 2 days, then 40 mg once daily for 2 days, then 80 mg once daily for 2 days, then 120 mg once daily; maximum dose 120 mg/day.
100 mg orally twice daily; may initiate at 50 mg twice daily and increase to 100 mg twice daily after 1 week.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours for levomilnacipran; at steady state, half-life supports once-daily dosing without extensive accumulation.
Approximately 11 hours for milnacipran (SAVELLA). In the context of twice-daily dosing, steady state is reached within 2-3 days.
Primarily renal (approximately 65% as unchanged levomilnacipran and 25% as N-desmethyllevomilnacipran); fecal excretion accounts for ~8%.
Renal excretion of unchanged drug and metabolites accounts for approximately 51-58% of the dose. Fecal excretion accounts for about 19-22%. The remainder is eliminated via other routes (e.g., oxidative metabolism and subsequent conjugation).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant